LAS VEGAS, March 1, 2007 (PRIME NEWSWIRE) -- Samaritan Pharmaceuticals Inc. (AMEX:LIV), a developer of innovative drugs, is pleased to announced today that the company has closed its acquisition of Metastatin Pharmaceuticals, Inc., a biopharmaceutical company focused on molecularly targeted Cancer drugs to control tumor progression and metastasis.
Lane Capital Markets served as an advisor in connection with this transaction.
About Samaritan Pharmaceuticals: "We LIV....to Save Lives."
Samaritan is a small-cap Biotech, driven to discover, develop and commercialize innovative therapeutics' for AIDS, Alzheimer's, Cancer and Heart disease patients. Look at http://www.samaritanpharma.com. Please register on Website so we can notify you of upcoming conference calls, news and events.
Samaritan Pharmaceuticals -- Samaritan Technology Videos: http://www.samaritanpharma.com/samaritan_mechanism_of_action_videos.asp
The Samaritan Pharmaceuticals Inc. logo is available at http://www.primezone.com/newsroom/prs/?pkgid=2670
Disclaimer
The company disclaims any information that is created by an outside party and endorses only information that is communicated by its press releases, filings and Website. This news release contains forward-looking statements that reflect management's current beliefs about the potential for its drug candidates, science and technology. However, as with any biopharmaceutical under development, there are significant risks and uncertainties in the process of development and regulatory review. There are no guarantees that products will prove to be commercially successful. For additional information about the factors that affect the company's business, please read the company's latest Form 10-K/A filed November 2, 2006. The company undertakes no duty to update forward-looking statements.